Gesynta Pharma is randomizing 50% of patients in a phase 2 endometriosis trial of Vipoglanstat.
Stockholm, June 17, 2026 /PRNewswire/ — Gesynta Pharma AB, a Swedish clinical-stage pharmaceutical company focused on chronic inflammatory diseases, today announced that 50% of the target of 190 patients have been randomized into a phase 2 clinical proof-of-concept (NOVA) trial. The study is evaluating feboglanstat, a new non-hormonal, non-opioid drug for the treatment of endometriosis. This painful, often debilitating, chronic inflammatory disease, which affects more than 10% of women of reproductive age, is also a major cause of infertility. The main results of the study are expected to appear in 2027.
The NOVA* trial is a randomized, double-blind, placebo-controlled, phase 2, proof-of-concept clinical trial evaluating feboglanstat in women with endometriosis across Europe. The trial is evaluating the efficacy and safety of two dose levels of feboglanstat and will provide important information for subsequent phase III program design.
“Reaching the halfway point in patient recruitment represents a major milestone in our phase 2 clinical trial in endometriosis,” says Eva Johnson, Chief Medical Officer (CMO) and Vice President of Clinical Development. “The rapid progress has been achieved well ahead of schedule and reflects strong participation from clinical sites and high interest among eligible participants. This momentum highlights the urgent need for better treatments.” “We are now keen to complete registration and move on to the next stage of evaluation.”
“The NOVA trial represents a major advance in an area with few ongoing clinical trials, and a major step toward creating a strong foundation for a future Phase III program for vipoglanstat,” comments Patrick Steinberg, CEO of Gesynta Pharma. “Given the enormous medical need, our focus remains on providing a highly effective, safe and well-tolerated treatment.”
Vipoglanstat is an innovative, orally active drug candidate designed to reduce pain and inflammation by targeting mPGES-1, a key enzyme that produces the proinflammatory mediator prostaglandin E2 (PGE2) in endometrial lesions. A preclinical proof-of-concept study in an advanced endometriosis model demonstrated that feboglanstat significantly reduced pain-related behaviors and endometriotic lesion burden. Previous clinical studies confirm its safety, tolerability, and positive pharmacodynamic effects in humans, supporting further development of the drug candidate as a non-hormonal, non-opioid treatment for endometriosis.
*NOVA: Non-Hormonal Option – Vipoglanstat Evaluation Trial
For more information, please contact:
Patrick Steinberg, CEO
Tel: +46 (0)733 83 66 70
Email: [email protected]
About the uterine lining
Endometriosis is a chronic, painful inflammatory disorder in which tissue similar to the endometrium grows outside the uterus, mainly in the pelvic cavity, causing inflammation, fibrosis, and the formation of endometrial lesions and adhesions. It typically presents with severe pain during menstruation (dysmenorrhea), pain between periods (nonmenstrual pelvic pain, NMPP), pain during intercourse (dyspareunia), gastrointestinal symptoms, and infertility. Current management is usually limited to analgesics, hormonal treatments, and surgery.
Despite its high prevalence, affecting more than 10% of women of reproductive age, endometriosis remains a severely underserved area of women’s health. This disease suffers from a significant lack of diagnosis and treatment, with few new treatment options available to patients. For millions of women around the world, dealing with severe pain coupled with these diagnostic and treatment hurdles makes living with endometriosis extremely difficult.
About Nova
The NOVA trial is a randomized, double-blind, placebo-controlled, phase 2 proof-of-concept clinical trial evaluating the drug candidate vipoglanstat in women with endometriosis across Europe. The trial is evaluating the efficacy and safety of two dose levels of feboglanstat and will provide important information for subsequent phase III program design.
Approximately 190 patients between the ages of 18 and 45 will receive feboglanstat or placebo over four menstrual cycles. The primary objective is to evaluate the effectiveness of feboglanstat on endometriosis-related pain during non-menstrual days. Secondary objectives include assessing the impact on menstrual pain (dysmenorrhea), pain during intercourse (dyspareunia), use of opioid rescue medications, and quality of life measures. Changes in endometrial lesions evaluated by MRI will be explored. Final results are expected to appear in 2027.
About Jesinta Pharma
Gesynta Pharma’s research into targeting mPGES-1, an enzyme key to inflammation, began at Karolinska Institutet in Sweden. The company’s lead compound, vipoglanstat, is in development for the treatment of endometriosis, offering a novel non-hormonal, non-opioid therapeutic approach to a chronic inflammatory condition that affects more than 10% of women of reproductive age. Vipoglanstat significantly reduced pain-related behaviors and endometriotic lesions in an advanced preclinical disease model. The drug candidate is currently being evaluated in a phase II NOVA proof-of-concept clinical trial.
The second drug candidate in Gesynta Pharma’s portfolio, GS-073, is ready to enter clinical phase I for the treatment of chronic inflammatory pain.
Gesynta Pharma’s shareholders include Hadean Ventures, Industrifonden, Innovestor Life Sciences, Linc, HealthCap, XGen Venture and other world-renowned specialist investors.
For more information, please visit www.gesynta.se
This information is provided to you by Cision http://news.cision.com
The following files are available for download:
View original content:https://www.prnewswire.com/apac/news-releases/gesynta-pharma-randomizes-50-of-patients-in-phase-2-endometriosis-trial-of-vipoglanstat-302802943.html
SOURCE Jesinta Pharma
